{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:40:32Z","timestamp":1792597232850,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008337","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000}}],"reference-count":354,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008337.pub2","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T17:17:39Z","timestamp":1386782259000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Optimum duration of regimens for <i>Helicobacter pylori<\/i> eradication"],"prefix":"10.1002","volume":"2013","author":[{"given":"Yuhong","family":"Yuan","sequence":"first","affiliation":[{"name":"McMaster University; Department of Medicine, Division of Gastroenterology; 1280 Main Street West Hamilton Ontario Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C","family":"Ford","sequence":"additional","affiliation":[{"name":"St. James's University Hospital; Department of Academic Medicine; Beckett Street Leeds UK LS9 7TF"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram J","family":"Khan","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Medicine, Division of Gastroenterology; 1280 Main Street West Hamilton Ontario Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IP), and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd); Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Forman","sequence":"additional","affiliation":[{"name":"International Agency for Research on Cancer; 150 cours Albert-Thomas Lyon France 69372"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios I","family":"Leontiadis","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Medicine, Division of Gastroenterology; 1280 Main Street West Hamilton Ontario Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Tse","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Medicine, Division of Gastroenterology; 1280 Main Street West Hamilton Ontario Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[{"name":"Hospital de Sabadell & Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd); Servei de Malalties Digestives; Parc Taul\u00ed, s\/n Sabadell Spain 08208"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fallone","sequence":"additional","affiliation":[{"name":"McGill University Health Centre; Faculty of Medicine; Royal Victoria Hospital 687 Pine Avenue West, Room R228 Montreal Quebec Canada H3A 1A1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Fischbach","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences; Department of Epidemiology; 4301 West Markham, # 820 Little Rock AR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Oderda","sequence":"additional","affiliation":[{"name":"Universita del Piemonte Orientale; Paediatric Endoscopy Units; Via Solaroli 17 Novara Italy 28100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Bazzoli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Bologna; Dipartimento di Scienze Mediche e Chirurgiche; Policlinico S.Orsola Via Massarenti 9, Via Borgo San Pietro 137 Bologna Italy I-40138"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[{"name":"McMaster University; Department of Medicine, Division of Gastroenterology; 1280 Main Street West Hamilton Ontario Canada L8S 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"issue":"5 part 1","key":"10.1002\/14651858.CD008337.pub2-BIB0001|cit1","first-page":"545","article-title":"Diagnosis and treatment of Helicobacter pylori infection. Relationship with gastrointestinal ulcer and antimicrobial resistance","volume":"61","author":"Antelo","year":"2001","journal-title":"Medicina (B Aires)"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ejim.2007.02.018","article-title":"Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases","volume":"18","author":"Aydin","year":"2007","journal-title":"European Journal of Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD008337.pub2-BIB0003|cit3","first-page":"1","article-title":"Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial","volume":"9","author":"Bago","year":"2010","journal-title":"Annals of Clinical Microbiology and Antimicrobials"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/ajg.2011.306","article-title":"A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori","volume":"106","author":"Basu","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0005|cit5","first-page":"355","article-title":"Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy","volume":"54","author":"Berrutti","year":"2008","journal-title":"Minerva Gastroenterologica e Dietologica"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1523-5378.2000.00012.x","article-title":"Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication ofHelicobacter pylori: a report from India","volume":"5","author":"Bhasin","year":"2000","journal-title":"Helicobacter"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1083-4389.2004.00265.x","article-title":"Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment","volume":"9","author":"Bosques-Padilla","year":"2004","journal-title":"Helicobacter"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1572-0241.2005.50019.x","article-title":"Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial","volume":"100","author":"Calvet","year":"2005","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1083-4389.2004.00208.x","article-title":"Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study","volume":"9","author":"Chaudhary","year":"2004","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0010|cit10","first-page":"A 62","article-title":"Clarithromycin and high dose omeprazole for H. pylori eradication: a comparison on one and two week therapy","volume":"106 (4, Pt2)","author":"Chew","year":"1994","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0011|cit11","first-page":"7","article-title":"The combination of omeprazole, amoxycillin, and clarithromycin eradicates Helicobacter pylori in 95% of patients --7 days of therapy is as good as 10 days","volume":"4","author":"Ching","year":"1998","journal-title":"Hong Kong Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0012|cit12","first-page":"207","article-title":"Analysis of eradication rate of Helicobacter pylori according to treatment duration by using 13C-Urea breath test comparison of OAC 7, 10 or 14 days regimen. [Korean]","volume":"23","author":"Cho","year":"2001","journal-title":"Korean Journal of Gastrointestinal Endoscopy"},{"issue":"18","key":"10.1002\/14651858.CD008337.pub2-BIB0013|cit13","first-page":"1245","article-title":"Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection. [Chinese]","volume":"82","author":"Cui M. Hu F. Jiang","year":"2002","journal-title":"Zheng X Zhonghua Yi Xue Za Zhi (Natlonal Medical Journal of China)"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1440-1746.2007.05029.x","article-title":"One-week versus two-week furazolidone-based quadruple therapy as the first-line treatment for Helicobacter pylori infection in Iran","volume":"22","author":"Daghaghzadeh","year":"2007","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1440-1746.1998.01557.x","article-title":"Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks?","volume":"13","author":"Dal Bo'","year":"1998","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1523-5378.2000.00006.x","article-title":"Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration","volume":"5","author":"Dammann","year":"2000","journal-title":"Helicobacter"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0017|cit17","first-page":"1993","article-title":"Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori","volume":"89","author":"Boer","year":"1994","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.dld.2003.12.015","article-title":"The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study","volume":"36","author":"Francesco","year":"2004","journal-title":"Digestive and Liver Disease"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00042737-200212000-00004","article-title":"Levofloxacin based regimens for the eradication of Helicobacter pylori","volume":"14","author":"Caro","year":"2002","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1590-8658(03)00409-2","article-title":"Use of bovine lactoferrin for Helicobacter pylori eradication","volume":"35","author":"Mario","year":"2003","journal-title":"Digestive and Liver Disease"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1523-5378.2011.00857.x","article-title":"Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days","volume":"16","author":"Dore","year":"2011","journal-title":"Helicobacter"},{"issue":"39","key":"10.1002\/14651858.CD008337.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.3748\/wjg.v12.i39.6310","article-title":"Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial","volume":"12","author":"Emami","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4318\/tjg.2010.0041","article-title":"Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia","volume":"21","author":"Er\u00e7in","year":"2010","journal-title":"Turkish Journal of Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD008337.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/archinte.158.15.1651","article-title":"A comparison of 10 and 14 days of lansoprazole triple therapy for eradication ofHelicobacter pylori","volume":"158","author":"Fennerty","year":"1998","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1523-5378.2009.00656.x","article-title":"Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens","volume":"14","author":"Filipec Kanizaj","year":"2009","journal-title":"Helicobacter"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0026|cit26","first-page":"71","article-title":"Helicobacter pylori eradication and its relation to antibiotic resistance and CYP2C19 status","volume":"99","author":"Garza Gonz\u00e1lez","year":"2007","journal-title":"Revista Espanola de Enfermedades Digestivas"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/j.1572-0241.2005.00178.x","article-title":"Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?","volume":"100","author":"Gisbert","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0028|cit28","first-page":"A121","article-title":"Clarithromycin, amoxicillin and omeprazole, for eradication of H. pylori: a prospective, randomized, comparative study of a seven day versus ten day course","volume":"110 Suppl 1","author":"Grade","year":"1996","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3748\/wjg.v10.i5.668","article-title":"Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey","volume":"10","author":"Gumurdulu","year":"2004","journal-title":"World Journal of Gastroenterology"},{"issue":"65","key":"10.1002\/14651858.CD008337.pub2-BIB0030|cit30","first-page":"1617","article-title":"One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of Helicobacter pylori infection","volume":"52","author":"Hsu","year":"2005","journal-title":"Hepato-Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0031|cit31","first-page":"246","article-title":"Comparison of 1 week and 2 weeks efficacy of lansoprazole triple therapy in treatment of H. pylori infection","volume":"8","author":"Hu","year":"1999","journal-title":"Chinese New Drugs Journal"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/147323000303100601","article-title":"Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer","volume":"31","author":"Hu","year":"2003","journal-title":"The Journal of International Medical Research"},{"issue":"14","key":"10.1002\/14651858.CD008337.pub2-BIB0033|cit33","first-page":"1161","article-title":"Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study","volume":"84","author":"China","year":"2004","journal-title":"Zhonghua Yi Xue Za Zhi (National Medical Journal of China)"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1365-2036.2000.00800.x","article-title":"Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease","volume":"14","author":"Hurenkamp","year":"2000","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0035|cit35","first-page":"A120. Abstract","article-title":"Significance of pretreatment of delta 13CO2 as predictor of success for H. pylori eradication","volume":"47 Suppl 3","author":"Kang","year":"2000","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0036|cit36","first-page":"407","article-title":"7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial","volume":"74","author":"Karatapanis","year":"2011","journal-title":"Acta Gastroenterologica Belgica"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0037|cit37","first-page":"A100. Abstract#","article-title":"Eradication of H. pylori infection with two triple-therapy regimens of 7, 10 and 14 days","volume":"41 Suppl 1","author":"Katicic","year":"1997","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00042737-200108000-00007","article-title":"Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial","volume":"13","author":"Kaviani","year":"2001","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0039|cit39","first-page":"433","article-title":"Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, Esomeprazole and lansoprazol (in Korean)","volume":"46","author":"Keum","year":"2005","journal-title":"Korean Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1523-5378.2007.00468.x","article-title":"Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea","volume":"12","author":"Kim","year":"2007","journal-title":"Helicobacter"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1523-5378.2008.00648.x","article-title":"Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea","volume":"13","author":"Kim","year":"2008","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0042|cit42","first-page":"76","article-title":"Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial","volume":"34 Suppl XI","author":"Kiyota","year":"1999","journal-title":"Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2036.1999.00485.x","article-title":"Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days","volume":"13","author":"Knigge","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2036.1996.111282000.x","article-title":"Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori","volume":"10","author":"Laine","year":"1996","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0045|cit45","first-page":"570. Abstract #","article-title":"Two weeks triple regimens with PPI, clarithromycin and amoxicillin is more effective in H. pylori eradication than one week triple regimens in patients with peptic ulcer disease in South Korea. (Multicenter trial by Korean Helicobacter pylori Study Group)","volume":"9 (5)","author":"Lee","year":"2004","journal-title":"Helicobacter"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2036.1998.00382.x","article-title":"Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin","volume":"12","author":"Louw","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2036.1998.00343.x","article-title":"Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing","volume":"12","author":"Louw","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0048|cit48","first-page":"87 Abstract #WS","article-title":"Eradication therapy for Helicobacter pylori infection in patients with duodenal ulcers based on furazolidone triple and quadruple therapy: A multicenter randomized controlled trial","volume":"16\u00a0Suppl 1","author":"Lv","year":"2011","journal-title":"Helicobacter"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1572-0241.2001.03519.x","article-title":"Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?","volume":"96","author":"Maconi","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1590-8658(00)80017-1","article-title":"Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?","volume":"32","author":"Maconi","year":"2000","journal-title":"Digestive and Liver Disease"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0051|cit51","first-page":"A192 Abstract #","article-title":"A prospective study comparing various anti-H. pylori treatment regimens for patients with peptic ulcer disease (PUD)","volume":"45 Suppl 5","author":"Mantzaris","year":"1999","journal-title":"Gut"},{"issue":"23","key":"10.1002\/14651858.CD008337.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.3748\/wjg.v11.i23.3566","article-title":"One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer","volume":"11","author":"Mesquita","year":"2005","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1523-5378.1996.tb00012.x","article-title":"Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori","volume":"1","author":"Moayyedi","year":"1996","journal-title":"Helicobacter"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0054|cit54","first-page":"A224","article-title":"Helicobacter pylori eradication with omeprazole, amoxicillin and clarithromycin: One week vs two weeks and reinfection rate at one year","volume":"112","author":"Mones","year":"1997","journal-title":"Gastroenterology"},{"issue":"29-30","key":"10.1002\/14651858.CD008337.pub2-BIB0055|cit55","first-page":"642","article-title":"Combined treatment of Helicobacter pylori infection--7-day or 14-day treatment?","volume":"47","author":"Muszynski","year":"1992","journal-title":"Polski Tygodnik Lekarski"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0056|cit56","first-page":"144","article-title":"A comparative study; one week treatment versus two weeks treatment with lansoprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer [Japanese]","volume":"57","author":"Nakagawa","year":"1999","journal-title":"Nippon Rinsho"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0057|cit57","first-page":"145","article-title":"Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomised study","volume":"44","author":"Palmas","year":"2002","journal-title":"Panminerva Medica"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008337.pub2-BIB0058|cit58","first-page":"A252-3. Abstrac","article-title":"A single-blind, monocentric study of four treatments for H. pylori eradication: an interim report","volume":"114","author":"Paoluzi","year":"1998","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1523-5378.2006.00459.x","article-title":"2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study","volume":"11","author":"Paoluzi","year":"2006","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0060|cit60","first-page":"A256. Abstract#","article-title":"The 10-day sequential therapy for Helicobacter pylori eradication in Korea: Less effective than expected","volume":"58 Suppl II","author":"Park","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0061|cit61","first-page":"265","article-title":"Decreasing eradication rate of Helicobacter pylori infection with metronidazole-based triple therapy. A randomised study","volume":"48","author":"Pellicano","year":"2002","journal-title":"Minerva Gastroenterologica e Dietologica"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2036.1998.00334.x","article-title":"Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer","volume":"12","author":"Pozzato","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"21","key":"10.1002\/14651858.CD008337.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.3748\/wjg.v13.i21.2967","article-title":"Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile","volume":"13","author":"Riquelme","year":"2007","journal-title":"World Journal of Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD008337.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3748\/wjg.14.2838","article-title":"Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?","volume":"14","author":"Robles-Jara","year":"\u00a02008","journal-title":"World Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.dld.2009.05.013","article-title":"Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment","volume":"42","author":"Sacco","year":"2010","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2036.1999.00436.x","article-title":"Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection","volume":"13","author":"Savarino","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1155\/2006\/258768","article-title":"Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen","volume":"20","author":"Scaccianoce","year":"2006","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0068|cit68","first-page":"251","article-title":"Triple therapies plus different probiotics for Helicobacter pylori eradication","volume":"12","author":"Scaccianoce","year":"2008","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0069|cit69","first-page":"A274. Abstract","article-title":"The comparison of the efficiency of the efficiency of one and two weeks lansoprazole, amoxycillin, clarithromycin (LAC) treatment protocols in the eradication of Helicobacter Pylori by using urea breath test","volume":"45 Suppl 5","author":"Simsek","year":"1999","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1523-5378.2010.00758.x","article-title":"High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication","volume":"15","author":"Sun","year":"2010","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0071|cit71","first-page":"470","article-title":"Probiotic supplementation improves tolerance to H. pylori eradication therapy in dyspeptic patients: preliminary data of a multicenter, controlled, double-blind randomized pilot study","volume":"13 (5)","author":"Suriani","year":"2008","journal-title":"Helicobacter"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2036.2004.02029.x","article-title":"Seven-day therapy for Helicobacter pylori in the United States","volume":"20","author":"Vakil","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2036.2000.00689.x","article-title":"Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study","volume":"14","author":"Wong","year":"2000","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0074|cit74","first-page":"1","article-title":"A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy","volume":"32","author":"Yang","year":"1999","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/gut.2006.102269","article-title":"Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study","volume":"56","author":"Zagari","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0076|cit76","first-page":"8\u201311","article-title":"Comparison of the efficacy of pantoprazole based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infection: A single-center, randomized, open and parallel-controlled study","volume":"14","author":"Zheng","year":"2009","journal-title":"Chinese Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0077|cit77","first-page":"A 109. Abstract","article-title":"Lactoferrin in a 7 days triple therapy forHelicobacter Pylori eradication: results of an open randomized trial","volume":"51 Suppl 3","author":"Aragona","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0078|cit78","first-page":"463. Abstract 1","article-title":"Lactoferrin in a 1-Week Triple Therapy for Eradication of H. pylori","volume":"8","author":"Aragona","year":"2003","journal-title":"Helicobacter"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0079|cit79","first-page":"Abstract M1505","article-title":"Lactoferrin in a one week triple therapy for eradication of H. pylori","volume":"124","author":"Aragona","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000051865","article-title":"Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study","volume":"63","author":"Armuzzi","year":"2001","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0081|cit81","first-page":"S404. Abstract","article-title":"A randomized open-label clinical trial with levofloxacin, omeprazole, Alinia (nitazoxanide) and doxycycline (LOAD) versus lansoprazole, amoxicillin and clarithromycin (LAC) in the treatment naive Helicobacter pylori population","volume":"104 Suppl 3","author":"Basu","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0082|cit82","first-page":"A24. Abstract 1","article-title":"A randomized open-label clinical trial with Levofloxacin, Omeprazole, Alinia (nitazoxanide), and Doxycycline (LOAD) versus Lansoprazole, Amoxicillin and Clarithromycin (LAC) in the treatment naive Helicobacter pylori population","volume":"136","author":"Basu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0083|cit83","first-page":"A6. Abstract 05","article-title":"Eradication of HP with omeprazole plus amoxicillin or amoxicillin and clarithromycin for 1 or 2 weeks in patients with duodenal ulcer","volume":"45 Suppl 5","author":"Bazzoli","year":"1999","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0084|cit84","first-page":"Abstract TH49","article-title":"Eradication of Helicobacter pylori and ulcer healing in patients with duodenal ulcer by one-week or two week omeprazole triple therapy","volume":"46 Suppl 2","author":"Bazzoli","year":"2000","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0085|cit85","first-page":"Abstract 2651","article-title":"Efficacy of omeprazole plus amoxicillin or amoxicillin plus clarithromycin for 1 week or 2 weeks for helicobacter pylori eradication in patients with duodenal ulcer","volume":"118 Suppl 2","author":"Bazzoli","year":"2000","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2036.1995.tb00349.x","article-title":"Rapid eradication of Helicobacter pylori infection","volume":"9","author":"Bell","year":"1995","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0087|cit87","first-page":"350","article-title":"Factors influencing the efficacy of first-line treatment of H. pylori injection in Algerian patients","volume":"14","author":"Boudjella","year":"2009","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0088|cit88","first-page":"8","article-title":"Tolerance, duration and efficacy of 5 and 7 days low-dose proton pump inhibitor triple Helicobacter pylori therapy compared to 10 days bismuth triple therapy","volume":"229","author":"Brecken","year":"1999","journal-title":"Scandinavian Journal of Gastroenterology. Supplement"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0089|cit89","unstructured":"Calderon IE Reed G Orozco A Blancas JM de Arino M Tamayo JL Open-label, multicenter, comparative study of therapy with triple drug trial for eradication of Helicobacter pylori with sodium rabeprazole, ofloxacin and amoxicillin. Comparative trial of 7 vs. 14 days treatment European Helicobacter Study Group. XVth International Workshop 2002; abstract book 2002 A98. Abstract 15.33"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1365-2036.2000.00744.x","article-title":"A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection","volume":"14","author":"Calvet","year":"2000","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD008337.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1046\/j.1365-2036.2001.01031.x","article-title":"What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis","volume":"15","author":"Calvet","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0092|cit92","first-page":"Abstract 11.13","article-title":"Randomised controlled trial comparing 7 vs. 10 days of triple therapy using rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori (Hp) eradication. Preliminary results","volume":"9","author":"Calvet","year":"2004","journal-title":"Helicobacter"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008337.pub2-BIB0093|cit93","first-page":"A425. Abstract","article-title":"Seven vs. ten-day rabeprazole triple therapy for Helicobacter Pylori eradication: a multicenter, randomized trial","volume":"128","author":"Calvet","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0094|cit94","first-page":"Abstract P750","article-title":"A new dual 7-day therapy is effective in eradicating Helicobacter pylori in duodenal ulcer patients","volume":"41 Suppl 3","author":"Cardelli","year":"1997","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0095|cit95","first-page":"A-581. Abstract","article-title":"Efficacy on eradication of H. pylori with three different schedules","volume":"120","author":"Castro","year":"2001","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s11695-010-0254-4","article-title":"Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery--fourteen days superior to seven days?","volume":"21","author":"Cerqueira","year":"2011","journal-title":"Obesity Surgery"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1440-1746.1995.tb01097.x","article-title":"Triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse: comparison of 1 week and 2 week regimens and recrudescence rates over 12 months","volume":"10","author":"Chen TS. Tsay SH. Chang FY. Lee","year":"1995","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0098|cit98","first-page":"799","article-title":"Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection [Chinese]","volume":"35","author":"Chen","year":"1996","journal-title":"Zhonghua Nei Ke Za Zhi (National Medical Journal of China)"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0099|cit99","first-page":"A145. Abstract","article-title":"Triple therapy with omeprazole, clarithromycin and amoxicillin for cure of Helicobacter pylori infection","volume":"39 Suppl 3","author":"Chen","year":"1996","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0100|cit100","first-page":"A87","article-title":"The combination of omeprazole, amoxycillin and clarithromycin eradicates Helicobacter Pylori in 95% of cases-7 day equals 10-days therapy","volume":"112 Suppl 1","author":"Ching","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0101|cit101","unstructured":"Choi M Oh JH Kwon JH Palk CN Park JM Choi YK Effect of CYP2C19 genotype on the eradication rate of Helicobacter pylori infection by pantoprazole based triple therapy in Koreans Gut 2006 abstract MON-G-51"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0102|cit102","first-page":"85. Abstract #6","article-title":"The 10-day sequential therapy for Helicobacter pylori eradication in Korea: Less effective than expected","volume":"40 Suppl 1","author":"Chun","year":"2010","journal-title":"International Journal of Medicine"},{"issue":"Suppl C","key":"10.1002\/14651858.CD008337.pub2-BIB0103|cit103","first-page":"R.0224","article-title":"One-week versus two-week furazolidone based quadruple therapy as the first-line treatment for Helicobacter pylori Infection in Iran","volume":"19","author":"Dagagzadeh","year":"2005","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0104|cit104","first-page":"A95. Abstract 0","article-title":"7 vs 14 day treatment with pantoprazole, clarithromycin and metronidazole for cure of H. pylori infection in duodenal ulcer patients","volume":"41 Suppl 1","author":"Dammann","year":"1997","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4038\/cmj.v49i4.1921","article-title":"Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study","volume":"49","author":"Silva","year":"2004","journal-title":"Ceylon Medical Journal"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0106|cit106","first-page":"Abstract 2534","article-title":"Efficacy of 5, 7, and 10 days levofloxacin-based dual therapy for H. pylori eradication","volume":"49 Suppl 3","author":"Caro","year":"2001","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0107|cit107","first-page":"A105. Abstract","article-title":"Efficacy of 5,7 and 10 days of levofloxacin-based dual therapy for H pylori eradication","volume":"49 Suppl 2","author":"Caro","year":"2001","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"A581. Abstract","DOI":"10.1016\/S0016-5085(08)82890-9","article-title":"Lack of efficacy of a levofloxacin-based dual therapy for H. Pylori eradication","volume":"120","author":"Caro","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0109|cit109","first-page":"A234. Abstract","article-title":"Different schedule of levofloxacin based therapy in H. pylori infection","volume":"17 Suppl","author":"Caro","year":"2002","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0110|cit110","first-page":"A271. Abstract","article-title":"Are 6 days of a triple clarithromycin based therapy sufficient to obtain the cure ofH. pylori infection?","volume":"45 Suppl 5","author":"Mario","year":"1999","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Di Mario F Aragona 1 G Dal Bo N Ingegnoli A Cavestro GM Moussa AM Potential use of lactoferrin in a 7 days triple therapy for Helicobacter pylori eradication: preliminary results European Helicobacter Study Group. XVth International Workshop; abstract book 2002 A98. Abstract 15.30","DOI":"10.1016\/S1590-8658(02)90081-2"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00004836-200305000-00006","article-title":"Use of lactoferrin for Helicobacter pylori eradication. Preliminary results","volume":"36","author":"Mario","year":"2003","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0113|cit113","first-page":"S340","article-title":"Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis","volume":"138","author":"Flores","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0114|cit114","first-page":"36B","article-title":"How can the current strategies for Helicobacter pylori eradication therapy be improved?","volume":"17 Suppl B","author":"Ford","year":"2003","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.7326\/0003-4819-147-8-200710160-00008","article-title":"Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication","volume":"147","author":"Fuccio","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1157\/13095927","article-title":"Seven or ten days? Cost-effectiveness study on the duration of H. pylori treatment in primary care","volume":"38","author":"Gen\u00e9","year":"2006","journal-title":"Atencion Primaria"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0117|cit117","first-page":"574. Abstract 1","article-title":"Randomized controlled trial: 7 vs. 14 days of a triple therapy of amoxicillin-clarithromycin rabeprazole for the eradication of Helicobacter pylori and its correlation with the CYP2C19 genotype","volume":"9","author":"Giasi-Gonzalez","year":"2004","journal-title":"Helicobacter"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0118|cit118","first-page":"530. Abstract 1","article-title":"Esomeprazole-based therapy in Helicobacter pylori eradication: Any effect by increasing the dose of esomeprazole or prolonging the treatment?","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"issue":"9790","key":"10.1002\/14651858.CD008337.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(11)60825-8","article-title":"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial","volume":"378","author":"Greenberg","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0120|cit120","first-page":"A136","article-title":"Randomized comparison of 1 week and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for the cure of Helicobacter pylori infection in gastric and duodenal ulcer patients","volume":"112 Suppl","author":"Habu","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/1319-3767.58762","article-title":"Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori","volume":"16","author":"Hasan","year":"2010","journal-title":"Saudi Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0122|cit122","first-page":"Abstract #95","article-title":"Initial therapy for Helicobacter pylori eradication in a Canadian real life setting: An interim analysis comparing 7 and 14 day triple therapy regimens","volume":"23","author":"Herba","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0123|cit123","first-page":"A159. Abstract","article-title":"Study of the usefulness of measurement of serum pepsinogen in eradication therapy of Helicobacter pylori","volume":"112 Suppl 1","author":"Iwasaki","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0124|cit124","first-page":"414. Abstract 1","article-title":"Effecacy of proton pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with chronic liver disease and peptic ulcer","volume":"11","author":"Jung","year":"2006","journal-title":"Helicobacter"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0125|cit125","first-page":"P-268. Abstract","article-title":"Comparison of the H. pylori eradication rate according to the duration of first-line triple therapy: a meta-analysis","volume":"134","author":"Jung","year":"2008","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1365-2036.2001.01072.x","article-title":"Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication","volume":"15","author":"Kamberoglou","year":"2001","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0127|cit127","first-page":"Abstract 4715","article-title":"Significance of pretreatment 13CO2 as predictor of success for H. pylori eradication","volume":"118 Suppl 2","author":"Kang","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0128|cit128","first-page":"A107. Abstract","article-title":"Rabeprazole 7-days vs rabeprazole 10-days triple therapy in the eradication of H. pylori infection - A randomized study","volume":"47 Suppl 1","author":"Karatapanis","year":"2000","journal-title":"Gut"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008337.pub2-BIB0129|cit129","first-page":"A-428. Abstract","article-title":"Rabeprazole 7-days vs. rabeprazole 10-days vs. rabeprazole 14 days triple therapy in the eradication of H. pylori infection- a randomized study","volume":"128","author":"Karatapanis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0130|cit130","first-page":"Abstract #Mon-G","article-title":"Triple regimen of variable duration (7 days vs 10 days vs 14 days), based on rabeprazole, in the eradication of Helicobacter pylori. A randomized study","volume":"56 (Suppl 3)","author":"Karatapanis","year":"2007","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0131|cit131","first-page":"A144. Abstract","article-title":"Eradication of H. pylori infection in peptic ulcers with four different drug regimens","volume":"39 Suppl 3","author":"Katicic","year":"1996","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0132|cit132","first-page":"386. Abstract #","article-title":"Eradication of Helicobacter pylori infection with two triple-therapy regimes of 7, 10, and 14 days; four years experience","volume":"11","author":"Katicic","year":"2006","journal-title":"Helicobacter"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/j.2055-2335.2010.tb00537.x","article-title":"Helicobacter pylori eradication regimens: Is there a difference?","volume":"40","author":"Khu","year":"2010","journal-title":"Journal of Pharmacy Practice and Research"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"A-583. Abstract","DOI":"10.1016\/S0016-5085(01)82902-4","article-title":"H. pylori eradication rate according to the duration of triple therapy in Korea: meta-analysis evaluation of H. pylori trial","volume":"120","author":"Kim","year":"2001","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008337.pub2-BIB0135|cit135","first-page":"Abstract G0736","article-title":"A multicenter randomized trial with twice daily ranitidine bismuth-citrate (R), metronidazole (M) and tetracycline (T) for 7 or 10 days for eradication of H-pylori infection","volume":"114","author":"Knigge","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0136|cit136","first-page":"A101. Abstract","article-title":"10 vs 14 day triple therapy with lansoprazole (Prevacid), amoxicillin, and clarithromycin in the eradication of Helicobacter pylori (Hp)","volume":"41 Suppl","author":"Krause","year":"1997","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0137|cit137","first-page":"491","article-title":"Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori","volume":"88","author":"Labenz","year":"1993","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0138|cit138","first-page":"A80-1. Abstract","article-title":"Lansoprazole (Lanso) 30 mg or 60 mg combined with two antibiotics (AMOX) and clarithromycin (Clari) to eradicate Helicobacter pylori (H. pylori)","volume":"43 Suppl 2","author":"Lamouliatte","year":"1998","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0139|cit139","first-page":"495","article-title":"Lansoprazole 30 mg or 60 mg combined with two antibiotics (amoxicillin and clarithromycin) to eradicate Helicobacter pylori in patients with duodenal ulcers [French]","volume":"24","author":"Lamouliatte","year":"2000","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0140|cit140","first-page":"S24. Abstract 7","article-title":"Rabeprazole-based triple therapy is safe and well tolerated in Helicobacter pylori eradication: findings from a large US multicenter trial","volume":"97 Suppl 9","author":"Lanza","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0141|cit141","first-page":"Abstract P745","article-title":"The patients' compliance of anti-Helicobacter pylori triple regimen with low dose clarithromycin in Korea","volume":"41 (UEGW Suppl)","author":"Lee","year":"1997","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0142|cit142","first-page":"605","article-title":"Triple therapy for eradication of H. pylori in patients with peptic ulcer [Korean]","volume":"31","author":"Lee","year":"1998","journal-title":"Korean Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0143|cit143","first-page":"579. Abstract 1","article-title":"Comparison of Helicobacter pylori eradication rate according to proton pump inhibitor-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole","volume":"9","author":"Lee","year":"2004","journal-title":"Helicobacter"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0144|cit144","first-page":"141","article-title":"The effect of Helicobacter pylori eradication on the improvement of the symptoms in patients with functional dyspepsia and peptic ulcer disease. [Korean]","volume":"71","author":"Lee","year":"2006","journal-title":"Korean Journal of Medicine"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S245. Abstract","DOI":"10.1016\/S0002-9270(02)05231-0","article-title":"Efficacy of different therapies for Helicobacter pylori eradication pylori eradication: A 5-year experience in a single center","volume":"97 Suppl","author":"Liao","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(11)60606-9","article-title":"10-Day and 14-day sequential therapy vs. standard triple therapy for helicobacter pylori infection in a Puerto Rican treatment-naive population: An interim analysis","volume":"140","author":"Lopez-Roman","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0147|cit147","first-page":"419. Abstract E","article-title":"One vs two week regimens of lansoprazole (L), amoxicillin (A), and clarithromycin (C) for duodenal ulcer (DU) healing and H. pylori (Hp) eradication","volume":"59 Suppl 3","author":"Maconi","year":"1998","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0148|cit148","first-page":"A5. Abstract 05","article-title":"Prolongation of a PPI-based triple therapy from one to two weeks is of benefit to patients with high H. pylori density and current smokers","volume":"45 Suppl V","author":"Maconi","year":"1999","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0149|cit149","first-page":"580. Abstract 1","article-title":"Results of eradication with classical triple and furazolidone-based regimens in patients with high bacterial density of Helicobacter pylori","volume":"9","author":"Makarenka","year":"2004","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0150|cit150","first-page":"535. Abstract #","article-title":"Eradication rate after randomized treatment in a population with high prevalence of Helicobacter pylori infection. Helicobacter","volume":"10","author":"Makarenka","year":"2005","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0151|cit151","first-page":"403","article-title":"H. pylori eradication by four triple therapies: Randomized study in double-blind","volume":"14 (4)","author":"Matougui","year":"2009","journal-title":"Helicobacter"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1523-5378.1998.08041.x","article-title":"Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population","volume":"3","author":"Miwa","year":"1998","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0153|cit153","first-page":"A7. Abstract W2","article-title":"Comparison of one and 2 weeks of lansoprazole, amoxycillin and clarithromycin in eradicating H.pylori","volume":"37 Suppl 2","author":"Moayyedi","year":"1995","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0154|cit154","first-page":"72","article-title":"Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy","volume":"34 Suppl XI","author":"Nishikawa","year":"1999","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0155|cit155","first-page":"Abstract #2679","article-title":"Triple therapy with faropenem against drug-resistant helicobacter pylori","volume":"118 Suppl 2","author":"Ogura","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1523-5378.2007.00551.x","article-title":"Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori","volume":"12","author":"Ogura","year":"2007","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0157|cit157","first-page":"Abstract MON-G-","article-title":"Effect of CYP2C19 genotype on the eradication rate of Helicobacter pylori infection by pantoprazole based triple therapy in Koreans","volume":"55 (UEGW suppl)","author":"Oh","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1523-5378.2007.00551.x","article-title":"Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori","volume":"12","author":"Ogura","year":"2007","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0159|cit159","first-page":"A 2545","article-title":"Two week PPI-based triple therapy with amoxycillin and clarithromycin has a higher efficacy in Helicobacter pylori eradication","volume":"49 Suppl 3","author":"Paoluzi","year":"2001","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0160|cit160","first-page":"A399-40. Abstra","article-title":"The 10-day sequential therapy for Helicobacter pylori eradication in Korea: Less effective than expected","volume":"136","author":"Park","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0161|cit161","first-page":"A127. Abstract.","article-title":"Eradication and reinfection rates after randomized treatment in a population with high prevalence of Helicobacter pylori infection","volume":"54 Suppl 7","author":"Pimanov","year":"2005","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0162|cit162","unstructured":"Rodionoff P Hyland L Ostapowicz N Triple therapy for Helicobacter pylori eradication: 1, 2 or 4 weeks? Sydney, Australia: World Congress of Gastroenterology August, 1990 Abstract PP938"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0163|cit163","first-page":"177","article-title":"Omeprazole, amoxicillin and clarithromycin in the treatment of helicobacter pylori, in 7 and 10-day regimens","volume":"23","author":"Rodr\u00edguez","year":"2003","journal-title":"Revista Gastroenterolog\u00eda del Per\u00fa"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0164|cit164","first-page":"549","article-title":"Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection","volume":"91","author":"Rodr\u00edguez T\u00e9llez","year":"1999","journal-title":"Revista Espa\u00f1ola de Enfermedades de Digestivas"},{"issue":"91-92","key":"10.1002\/14651858.CD008337.pub2-BIB0165|cit165","first-page":"722","article-title":"Azithromycin effect on helicobacter pylori eradication: double blind randomized clinical trial","volume":"56","author":"Rogha","year":"2009","journal-title":"Hepatogastroenterology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0166|cit166","first-page":"A24. Abstract 1","article-title":"Effect of three different regimens with esomeprazole, amoxicillin, and moxifloxacin in the treatment of primary H. pylori Infection","volume":"134","author":"Sacco","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"A207","DOI":"10.1016\/0016-5085(95)23488-8","article-title":"Clarithromycin for the cure of H.pylori infection: one or 2 weeks of treatment?","volume":"108","author":"Salandin","year":"1995","journal-title":"Gastroenterology"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0168|cit168","first-page":"S21. Abstract 6","article-title":"Helicobacter pylori eradication with rabeprazole-based triple therapy: findings in 803 patients with antibiotic-sensitive and resistant strains","volume":"97","author":"Schwartz","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0169|cit169","first-page":"A24. Abstract P","article-title":"Three weeks triple therapy is better than two or one week therapy for eradication of Helicobacter pylori in peptic ulcer disease","volume":"17 Suppl","author":"Sharma","year":"2002","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0170|cit170","first-page":"A103. Abstract","article-title":"Reinfection rate of Helicobacter Pylori infection after one and two weeks triple. A 17-month follow-up study","volume":"47 Suppl 3","author":"Simsek","year":"2000","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0171|cit171","first-page":"A150","article-title":"Eradication of helicobacter pylori with 10 or 14 days of bismuth triple regimes","volume":"35 Suppl IV","author":"Utzon","year":"1994","journal-title":"Gut"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0149-2918(00)80009-0","article-title":"Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population","volume":"21","author":"Uygun","year":"1999","journal-title":"Clinical Therapeutics"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0173|cit173","first-page":"A 65. Abstract","article-title":"A prospective, controlled, randomised trial of 3-,7- and 10-day rabeprazole based triple therapy for H. pylori eradication in the USA","volume":"122","author":"Vakil","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0174|cit174","unstructured":"Vakil N Schwarz H Lanza F Hahne W Barth J Seven-day rabeprazole-based triple therapy for H. pylori eradication is as effective as 10-day omeprazole-based triple therapy European Helicobacter Study Group. XVth International Workshop 2002. Abstract book 2002 A95. Abstract 15.19"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0175|cit175","unstructured":"Vakil N Kovacs T Ignatowitz W Hahne W Barth J Presence or absence of peptic ulcer disease does not affect H. pylori eradication rates with rabeprazole-based triple therapy European Helicobacter Study Group. XVth International Workshop 2002. Abstract book 2002 A95. Abstract 15.09"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0176|cit176","first-page":"A215. Abstract","article-title":"Antibiotic resistance accounts for only one third of treatment failures with triple therapy for H.pylori","volume":"51 Suppl 3","author":"Vakil","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0177|cit177","first-page":"A110. Abstract","article-title":"Safety and tolerability of rabeprazole-based triple therapy for Helicobacter eradication in a large US trial","volume":"51 Suppl 3","author":"Vakil","year":"2002","journal-title":"Gut"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0178|cit178","first-page":"A9. Abstract 63","article-title":"Antibiotic sensitivity in a large US multicenter trial of rabeprazole-based triple therapy for H. pylori eradication","volume":"122","author":"Vakil","year":"2002","journal-title":"Gastroenterology"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0179|cit179","first-page":"S17. Abstract 5","article-title":"Racial demographics do not affect efficacy of rabeprazole-based triple therapy for Helicobacter pylori eradication","volume":"97","author":"Vakil","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0180|cit180","first-page":"S21. Abstract 6","article-title":"Consistent Helicobacter pylori eradication rates with rabeprazole-based triple therapy across demographic subgroups","volume":"97","author":"Vakil","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0181|cit181","first-page":"Abstract M1495","article-title":"Clarithromycin resistance and H. pylori eradication rates in US racial groups with rabeprazole-based triple therapy","volume":"123","author":"Vakil","year":"2003","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0182|cit182","first-page":"Abstract S1244","article-title":"Density of Helicobacter pylori (Hp) organisms does not affect eradication rates in peptic ulcer disease (PUD) and non-peptic ulcer disease (NPUD)","volume":"123","author":"Vakil","year":"2003","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0183|cit183","first-page":"Abstract 771","article-title":"The effect of gastritis on Helicobacter pylori (Hp) eradication rates with triple therapy","volume":"123","author":"Vakil","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0184|cit184","first-page":"205","article-title":"Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children","volume":"9","author":"Xiang L. Wen FQ. Zuo WH. Tang","year":"2007","journal-title":"Zhongguo Dangdai Erke Zazhi. (Chinese Journal of Contemporary Pediatrics)"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0185|cit185","first-page":"333. Abstract W","article-title":"Analysis of related factors of H. pylori eradication therapy efficiency","volume":"14","author":"Zhou","year":"2009","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0186|cit186","first-page":"A120. Abstract","article-title":"Helicobacter pylori eradication with 7-day triple therapy, 10-day regimen, and sequential therapy","volume":"53 Suppl 6","author":"Zullo","year":"2004","journal-title":"Gut"},{"issue":"14","key":"10.1002\/14651858.CD008337.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.11569\/wcjd.v21.i14.1366","article-title":"Furazolidone-based quadruple therapy as first-line treatment for Helicobacter pylori infection","volume":"21","author":"Chen","year":"2013","journal-title":"World Chinese Journal of Digestology"},{"issue":"19","key":"10.1002\/14651858.CD008337.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3748\/wjg.v18.i19.2377","article-title":"Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection","volume":"18","author":"Choi","year":"2012","journal-title":"World Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008337.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2013\/801915","article-title":"Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada","volume":"27","author":"Fallone","year":"2013","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0190|cit190","first-page":"66","article-title":"Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy","volume":"84","author":"Konorev","year":"2012","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0191|cit191","unstructured":"Lv N Xie Y Chen Y Wang J Liu W Zhang Z Furazolidone-based triple and quadruple eradication therapy for H. pylori infection Journal of Gastroenterology and Hepatology 2013 1-22. Abastract 00029"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0192|cit192","doi-asserted-by":"crossref","unstructured":"Prasertpetmanee S Mahachai V Vilaichone R Reliable efficacy of 14-day high dose PPI triple therapy for helicobacter pylori eradication independent effect of CYP2C19 genotype and high prevalence of metronidazole resistance in Thailand Helicobacter 2012 99","DOI":"10.1016\/S0016-5085(12)61854-X"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0193|cit193","doi-asserted-by":"crossref","unstructured":"Prasertpetmanee S Mahachai V Vilaichone RK High efficacy of 14-day high dose PPI triple therapy for H. pylori eradication independent effect of CYP2C19 genotype in Thailand Journal of Gastroenterology and Hepatology 2012 61","DOI":"10.1016\/S0016-5085(12)61854-X"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0194|cit194","doi-asserted-by":"crossref","unstructured":"Prasertpetmanee S Mahachai V Vilaichone RK Improved efficacy of PPI-amoxicillin-clarithromycin triple therapy for H. Pylori eradication in low clarithromycin resistance areas or for tailored therapy Gastroenterology 2013 S332","DOI":"10.1016\/S0016-5085(13)61217-2"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/hel.12041","article-title":"Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy","volume":"18","author":"Prasertpetmanee","year":"2013","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0196|cit196","doi-asserted-by":"crossref","unstructured":"Prasertpetmanee S Mahachai V Vilaichone RK Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy Helicobacter 2013 270 273","DOI":"10.1111\/hel.12041"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0197|cit197","doi-asserted-by":"crossref","unstructured":"Prasertpetmanee S Mahachai V Vilaichone RK Reliable efficacy of 14-day high dose PPI triple therapy for helicobacter pylori eradication in non-ulcer dyspeptic patients in Thailand Gastroenterology 2012 S487","DOI":"10.1016\/S0016-5085(12)61854-X"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0198|cit198","doi-asserted-by":"crossref","unstructured":"Vilaichone RK Prasertpetmanee S Mahachai V Reliable efficacy of 14-day high dose PPI triple therapy for helicobacter pylori eradication independent effect of CYP2C19 genotype and high prevalence of metronidazole resistance in Thailand American Journal of Gastroenterology 2012 S46. Abstract 105","DOI":"10.14309\/00000434-201210001-00105"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0199|cit199","unstructured":"Wang SJ Wang WH Chi YX Teng GG Concomitant therapy with four drugs is more effective than triple therapy for H. pylori eradication Journal of Gastroenterology and Hepatology 2013 543. Abstract P1373"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0200|cit200","first-page":"5","article-title":"Evaluation of bismuth-clarithromycin-containing quadruple therapy for initial Helicobacter pylori eradication","volume":"17","author":"Xu","year":"2012","journal-title":"Chinese Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0201|cit201","first-page":"351","article-title":"Update on Helicobacter pylori treatment","volume":"75","author":"Ables","year":"2007","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","article-title":"Meta-analysis, Simpson's paradox, and the number needed to treat","volume":"2","author":"Altman","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-5378.2009.00738.x","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition","volume":"15","author":"Asaka","year":"2010","journal-title":"Helicobacter"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0204|cit204","first-page":"33","article-title":"Pylera plus omeprazole: quadruple treatment for Helicobacter pylori","volume":"8","author":"Baker","year":"2008","journal-title":"Reviews in Gastroenterological Disorders"},{"issue":"7","key":"10.1002\/14651858.CD008337.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/ajg.2012.111","article-title":"Response to Yuan and Leontiadis (Letters to the editor)","volume":"107","author":"Basu","year":"2012","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2036.2003.01396.x","article-title":"Risk factors for failure of Helicobacter pylori therapy-- results of an individual data analysis of 2751 patients","volume":"17","author":"Broutet","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1592\/phco.19.4.324.30939","article-title":"Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis","volume":"19","author":"Buring","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"33","key":"10.1002\/14651858.CD008337.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.3748\/wjg.v12.i33.5311","article-title":"First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004","volume":"12","author":"Buz\u00e1s","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"624","DOI":"10.7326\/0003-4819-148-8-200804150-00009","article-title":"Could increasing the duration of triple therapy be a clinically useful strategy?","volume":"148","author":"Calvet","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson's paradox and calculation of number needed to treat from meta-analysis","volume":"2","author":"Cates","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1523-5378.2007.00556.x","article-title":"Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate","volume":"12","author":"Choi","year":"2007","journal-title":"Helicobacter"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bpobgyn.2004.10.011","article-title":"Individual patient data meta-analyses","volume":"19","author":"Clarke","year":"2005","journal-title":"Best Practice and Research. Clinical Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0217|cit217","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"6602","key":"10.1002\/14651858.CD008337.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/bmj.295.6602.814","article-title":"Determinants of non-compliance with short term antibiotic regimens","volume":"295","author":"Cockburn","year":"1987","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1037\/h0026256","article-title":"Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit","volume":"70","author":"Cohen","year":"1968","journal-title":"Psychological Bulletin"},{"issue":"6977","key":"10.1002\/14651858.CD008337.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"issue":"6970","key":"10.1002\/14651858.CD008337.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/bmj.309.6970.1677","article-title":"The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?","volume":"309","author":"Counsell","year":"1994","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1440-1746.1998.01557.x","article-title":"Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks?","volume":"13","author":"Dal Bo'","year":"1998","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0223|cit223","first-page":"409","article-title":"Worldwide H. pylori antibiotic resistance: a systematic review","volume":"19","author":"Francesco","year":"2010","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s10620-006-9210-5","article-title":"Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys","volume":"51","author":"Martel","year":"2006","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1-2","key":"10.1002\/14651858.CD008337.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000090315","article-title":"'Rescue' therapies for the management of Helicobacter pylori infection","volume":"24","author":"Mario","year":"2006","journal-title":"Digestive Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1005457226341","article-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach","volume":"45","author":"Dore","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"issue":"7109","key":"10.1002\/14651858.CD008337.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7121","key":"10.1002\/14651858.CD008337.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7109","key":"10.1002\/14651858.CD008337.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1523-5378.2009.00671.x","article-title":"Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing \"concomitant therapy\" versus triple therapy for Helicobacter pylori eradication","volume":"14","author":"Essa","year":"2009","journal-title":"Helicobacter"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ije\/31.1.128","article-title":"Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis","volume":"31","author":"Fischbach","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1440-1746.2008.05314.x","article-title":"Asia-Pacific consensus guidelines on gastric cancer prevention","volume":"23","author":"Fock","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1440-1746.2009.05982.x","article-title":"Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection","volume":"24","author":"Fock","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1572-0241.2004.40014.x","article-title":"Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis","volume":"99","author":"Ford","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0238|cit238","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003840.pub4","article-title":"Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients","author":"Ford","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"48","key":"10.1002\/14651858.CD008337.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.3748\/wjg.14.7361","article-title":"Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis","volume":"14","author":"Ford","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-5378.2010.00779.x","article-title":"Epidemiology of Helicobacter pylori infection and public health implications","volume":"15 Suppl 1","author":"Ford","year":"2010","journal-title":"Helicobacter"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ajg.2009.658","article-title":"Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome","volume":"105","author":"Ford","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0242|cit242","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002298","article-title":"Therapies for the eradication of Helicobacter pylori","author":"Forman","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0243|cit243","unstructured":"Forman D Delaney B Kuipers E Malthaner R Moayyedi P Gardener E Cochrane Upper Gastrointestinal and Pancreatic Diseases Grouop About The Cochrane Collaboration (Cochrane Review Groups (CRGs) 2009"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD008337.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S0016-5085(97)80032-7","article-title":"What remaining questions regarding Helicobacter pylori and associated diseases should be addressed by future research? View from North America","volume":"113","author":"Freston","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Medical Research Methodology"},{"issue":"a1454","key":"10.1002\/14651858.CD008337.pub2-BIB0246|cit246","first-page":"746","article-title":"Treatment of Helicobacter pylori infection","volume":"337","author":"Fuccio","year":"2008","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/ajg.2009.458","article-title":"Was it really an \"ugly\" meta-analysis?","volume":"104","author":"Fuccio","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","article-title":"Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori","volume":"81","author":"Furuta","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1038\/ajg.2009.555","article-title":"Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children","volume":"104","author":"Gatta","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gen\u00e9","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1365-2036.2003.t01-1-01712.x","article-title":"Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis","volume":"18","author":"Gen\u00e9","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1523-5378.1999.09038.x","article-title":"Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review","volume":"4","author":"Gisbert","year":"1999","journal-title":"Helicobacter"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00042737-200111000-00007","article-title":"Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia","volume":"13","author":"Gisbert","year":"2001","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"41","key":"10.1002\/14651858.CD008337.pub2-BIB0255|cit255","first-page":"1383","article-title":"Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia?","volume":"48","author":"Gisbert","year":"2001","journal-title":"Hepatogastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2036.2003.01766.x","article-title":"Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication","volume":"18","author":"Gisbert","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0257|cit257","first-page":"83","article-title":"Potent gastric acid inhibition in Helicobacter pylori eradication","volume":"65 Suppl 1","author":"Gisbert","year":"2005","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1523-5378.2007.00576.x","article-title":"Evolution of Helicobacter pylori therapy from a meta-analytical perspective","volume":"12 Suppl 2","author":"Gisbert","year":"2007","journal-title":"Helicobacter"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2036.2011.04770.x","article-title":"Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori","volume":"34","author":"Gisbert","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ajg.2012.132","article-title":"Long-term follow-up of 1,000 patients cured ofHelicobacter pylori infection following an episode of peptic ulcer bleeding","volume":"107","author":"Gisbert","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0261|cit261","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/ebm.13.4.128","article-title":"Glossary","volume":"13","author":"Anonymous","year":"2008","journal-title":"Evidence-based Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"Gluud","year":"2006","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-6-3","article-title":"Room for improvement? A survey of the methods used in systematic reviews of adverse effects","volume":"6","author":"Golder","year":"2006","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ajg.2011.1","article-title":"Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: A long-term follow-up in a high-risk Area in Spain","volume":"106","author":"Gonzalez","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ncpgasthep1138","article-title":"New concepts of resistance in the treatment of Helicobacter pylori infections","volume":"5","author":"Graham","year":"2008","journal-title":"Nature Clinical Practice. Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"issue":"20","key":"10.1002\/14651858.CD008337.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"20","key":"10.1002\/14651858.CD008337.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"7501","key":"10.1002\/14651858.CD008337.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/bmj.38446.498542.8F","article-title":"Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey","volume":"330","author":"Haynes","year":"2005","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD008337.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0273|cit273","unstructured":"PT Higgins JPT Altman DG AC Sterne JAC Cochrane Statistical Methods Group and the Cochrane\u00a0Bias Methods Group (editors) Chapter 8: Assessing\u00a0risk\u00a0of\u00a0bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0274|cit274","first-page":"44","article-title":"Amoxicillin for the treatment of Helicobacter pylori infection","volume":"31 Suppl 9","author":"Hirschl","year":"1996","journal-title":"Journal of Gastroenterology"},{"issue":"7211","key":"10.1002\/14651858.CD008337.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1572-0241.1998.00684.x","article-title":"Guidelines for the management of Helicobacter pylori infection","volume":"93","author":"Howden","year":"1998","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2036.1999.00530.x","article-title":"The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole","volume":"13","author":"Huang","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"18","key":"10.1002\/14651858.CD008337.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.3748\/wjg.v11.i18.2726","article-title":"Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review","volume":"11","author":"Huang","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/00365529609094743","article-title":"The role of Helicobacter pylori in pathogenesis: the spectrum of clinical outcomes","volume":"220","author":"Hunt","year":"1996","journal-title":"Scandinavian Journal of Gastroenterology. Supplement"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1155\/1998\/170180","article-title":"Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology","volume":"12","author":"Hunt","year":"1998","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1155\/1999\/180751","article-title":"Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group","volume":"13","author":"Hunt","year":"1999","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1155\/2004\/326767","article-title":"Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection","volume":"18","author":"Hunt","year":"2004","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0283|cit283","first-page":"299","article-title":"Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"Hunt","year":"2011","journal-title":"Journal of Gastrointestinal & Liver Diseases."},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03256810","article-title":"Misleading statistics: The problems surrounding number needed to treat and number needed to harm","volume":"24","author":"Hutton","year":"2010","journal-title":"Pharmaceutical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.285.4.437","article-title":"Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas","volume":"285","author":"Ioannidis","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"CMAJ"},{"issue":"7303","key":"10.1002\/14651858.CD008337.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1053\/gast.2002.37051","article-title":"A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study","volume":"123","author":"Katelaris","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ajg.2010.457","article-title":"Nodal relapse after Helicobacter pylori eradication in a patient with primary localized gastric mucosa-associated Lymphoid tissue lymphoma","volume":"106","author":"Kato","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD008337.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"A-583. Abstract","DOI":"10.1016\/S0016-5085(01)82902-4","article-title":"H. pylori eradication rate according to the duration of triple therapy in Korea: meta-analysis evaluation of H. pylori trial","volume":"120","author":"Kim","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1523-5378.2012.00943.x","article-title":"Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study","volume":"17","author":"Kudo","year":"2012","journal-title":"Helicobacter"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1572-0241.2003.t01-1-07288.x","article-title":"Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial","volume":"98","author":"Laine","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ajg.2011.480","article-title":"Management of Patients With Ulcer Bleeding","volume":"107","author":"Laine","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1746.1998.tb00537.x","article-title":"Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection","volume":"13","author":"Lam","year":"1998","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"Oct 22","key":"10.1002\/14651858.CD008337.pub2-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apm.12009","article-title":"Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway","volume":"[Epub ahead of","author":"Larsen","year":"2012","journal-title":"APMIS"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14656566.1.3.507","article-title":"Clarithromycin for Helicobacter pylori infection","volume":"1","author":"Leung","year":"2000","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"9862","key":"10.1002\/14651858.CD008337.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2036.1998.00382.x","article-title":"Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin","volume":"12","author":"Louw","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0299|cit299","first-page":"S397-8. Abstrac","article-title":"Triple versus quadruple therapy as primary treatment for Helicobacter pylori infection: a meta-analysis of efficacy and tolerability","volume":"103 Suppl 1","author":"Luther","year":"2008","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection--the Maastricht IV\/ Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/MOG.0b013e32835918a7","article-title":"Helicobacter pylori: clinical management","volume":"28","author":"Malfertheiner","year":"2012","journal-title":"Current Opinion in Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","article-title":"Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report","volume":"16","author":"Malfertheiner","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.0953-0673.1996.00241.x","article-title":"Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture","volume":"10","author":"McColm","year":"1996","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2036.2012.05211.x","article-title":"Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection","volume":"36","author":"McNicholl","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/bmj.321.7262.659","article-title":"Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia","volume":"321","author":"Moayyedi","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0308|cit308","first-page":"10","article-title":"Clinical and economic consequences of dyspepsia in the community","volume":"50 Suppl 4","author":"Moayyedi","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/j.1572-0241.2003.08724.x","article-title":"An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews","volume":"98","author":"Moayyedi","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1111\/j.1572-0241.2004.40948.x","article-title":"Meta-analysis: Can we mix apples and oranges?","volume":"99","author":"Moayyedi","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bpg.2006.11.004","article-title":"The health economics of Helicobacter pylori infection","volume":"21","author":"Moayyedi","year":"2007","journal-title":"Best Practice and Research. Clinical Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008337.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/ajg.2009.563","article-title":"Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?","volume":"104","author":"Moayyedi","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0313|cit313","first-page":"1339","article-title":"Intention-to-treat principle","volume":"165","author":"Montori","year":"2001","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-2-2","article-title":"Pooling data for number needed to treat: no problems for apples","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Medical Research Methodology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11908-005-0071-4","article-title":"Update on therapeutic options for Helicobacter pylori-related diseases","volume":"7","author":"M\u00e9graud","year":"2005","journal-title":"Current Infectious Disease Reports"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0316|cit316","unstructured":"AstraZeneca Pharmaceuticals LP The label approved on 01\/20\/2012 (PDF) for NEXIUM, NDA no. 022101 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021153s040,021957s011,022101s008lbl.pdf"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0317|cit317","first-page":"65","article-title":"Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease","volume":"272","author":"NIH Consensus","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/acm.2005.11.205","article-title":"\"No language restrictions\" in database searches: what does this really mean?","volume":"11","author":"Pilkington","year":"2005","journal-title":"Journal of Alternative and Complementary Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008337.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1590-8658(00)80327-8","article-title":"Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study","volume":"32","author":"Pilotto","year":"2000","journal-title":"Digestive and Liver Disease"},{"issue":"102-103","key":"10.1002\/14651858.CD008337.pub2-BIB0320|cit320","first-page":"1074","article-title":"Lafutidine-based triple therapy for Helicobacter pylori eradication","volume":"57","author":"Ren","year":"2010","journal-title":"Hepatogastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0321|cit321","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"5","key":"10.1002\/14651858.CD008337.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1155\/2007\/419784","article-title":"A meta-analysis of the success rate of Helicobacter pylori therapy in Canada","volume":"21","author":"Rodgers","year":"2007","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ajg.2008.87","article-title":"Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen","volume":"104","author":"Rokkas","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ajg.2011.2","article-title":"Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression","volume":"106","author":"Sanchez-Delgado","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ajg.2011.106","article-title":"Small intestinal bacterial overgrowth and Helicobacter pylori: Can they be cause of thrombocytopenia in patients with chronic liver disease","volume":"106","author":"Savarino","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00045391-199901000-00005","article-title":"Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials","volume":"6","author":"Schmid","year":"1999","journal-title":"American Journal of Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-9-10","article-title":"Overstating the evidence: double counting in meta-analysis and related problems","volume":"9","author":"Senn","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1191\/1740774505cn087oa","article-title":"Meta-analysis of individual patient data from randomized trials: a review of methods used in practice","volume":"2","author":"Simmonds","year":"2005","journal-title":"Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2125.2005.02441.x","article-title":"Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication","volume":"60","author":"Sp\u00e9nard","year":"2005","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0330|cit330","unstructured":"StatsDirect Ltd StatsDirect\u00ae 2012"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD008337.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ncpgasthep1353","article-title":"High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication","volume":"6","author":"Sugimoto","year":"2009","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2036.2009.03960.x","article-title":"Systematic review: the global incidence and prevalence of peptic ulcer disease","volume":"29","author":"Sung","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008337.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1572-0241.2005.00225.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia","volume":"100","author":"Talley","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2005.09.020","article-title":"American Gastroenterological Association technical review on the evaluation of dyspepsia","volume":"129","author":"Talley","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archinte.1997.00440220091012","article-title":"Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori","volume":"157","author":"Taylor","year":"1997","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD008337.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1055\/s-2000-7530","article-title":"Treating H. pylori shorter than one week--a real future perspective?","volume":"38","author":"Treiber","year":"2000","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0339|cit339","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000030.pub2","article-title":"Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals","author":"Turner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0340|cit340","first-page":"174","article-title":"Poor efficacy of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori eradication","volume":"26","author":"Uygun","year":"2007","journal-title":"Indian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008337.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ajg.2008.91","article-title":"H. pylori treatment: new wine in old bottles?","volume":"104","author":"Vakil","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.2002.01270.x","article-title":"Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis","volume":"16","author":"Vallve","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2003.01746.x","article-title":"Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication","volume":"18","author":"Vergara","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.gtc.2006.03.004","article-title":"Helicobacter pylori diagnosis and management","volume":"35","author":"Vilaichone","year":"2006","journal-title":"Gastroenterology Clinics of North America"},{"issue":"7","key":"10.1002\/14651858.CD008337.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2036.2008.03807.x","article-title":"Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication","volume":"28","author":"Villoria","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD008337.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/ajg.2011.309","article-title":"Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen","volume":"106","author":"Watson","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3163\/1536-5050.95.2.117","article-title":"Response to Glanville et al.: How to identify randomized controlled trials in MEDLINE: ten years on","volume":"95","author":"Wilczynski","year":"2007","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD008337.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bpg.2006.11.001","article-title":"Treatment of Helicobacter pylori","volume":"21","author":"Wolle K. Malfertheiner","year":"2007","journal-title":"Best Practice & Research. Clinical Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0349|cit349","first-page":"415","article-title":"Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"4","key":"10.1002\/14651858.CD008337.pub2-BIB0350|cit350","first-page":"451","article-title":"Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0351|cit351","doi-asserted-by":"crossref","unstructured":"Yuan Y Hunt RH Response to Fuccio et al Was it really an \"ugly\" meta-analysis? American Journal of Gastroenterology 2009 2853 4","DOI":"10.1038\/ajg.2009.461"},{"issue":"7","key":"10.1002\/14651858.CD008337.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/ajg.2012.109","article-title":"Levofloxacin-based three-antibiotic regimen for H. pylori eradication (Letters to the editor)","volume":"107","author":"Yuan","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008337.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-5378.2008.00643.x","article-title":"Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis","volume":"13","author":"Zhao","year":"2008","journal-title":"Helicobacter"},{"key":"10.1002\/14651858.CD008337.pub2-BIB0354|cit354","doi-asserted-by":"publisher","first-page":"[Epub ahead of","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study","volume":"Jun 5. pii: S22","author":"Zullo","year":"2013","journal-title":"Clinics and Research in Hepatology and Gastroenterology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008337.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:35:55Z","timestamp":1740069355000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008337.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Upper GI and Pancreatic Diseases Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":354,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008337.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}